Long-Term Ibrutinib Therapy Reverses CD8<sup>+</sup> T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia.

Patients who achieved a CR with ibrutinib treatment, also tended to have a lower frequency of PD-1 CD8+ T cells prior to commencing therapy, although this did not reach statistical significance (24.05 vs. 35.3%; p = 0.130).

also in 111,027 other papers